Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Treatment of scleroderma

A C Gelber1, F M Wigley

  • 1Johns Hopkins University School of Medicine, Division of Molecular and Clinical Rheumatology, Baltimore, MD 21205, USA.

Current Opinion in Rheumatology
|November 1, 1995
PubMed
Summary

This year saw no new scleroderma treatments, but significant progress in research methodology. New guidelines for systemic sclerosis clinical trials were published, emphasizing careful design to assess treatment impact.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hickam's dictum and the rare convergence of antisynthetase syndrome and hemoglobin SC disease.

QJM : monthly journal of the Association of Physicians·2014
Same author

Renal biopsy in the management of lupus nephritis during pregnancy.

Lupus·2014
Same author

The "tank top sign": a unique pattern of skin fibrosis seen in pansclerotic morphea.

Annals of the rheumatic diseases·2009
Same author

Disproportionate elevation of N-terminal pro-brain natriuretic peptide in scleroderma-related pulmonary hypertension.

The European respiratory journal·2009
Same author

Fatigue: an overlooked determinant of physical function in scleroderma.

Rheumatology (Oxford, England)·2008
Same author

Management of Severe Raynaud's Phenomenon.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases·2008

Area of Science:

  • Rheumatology
  • Clinical Trial Design
  • Systemic Sclerosis Research

Background:

  • Scleroderma research is advancing, focusing on improving investigative approaches.
  • Recent publications highlight the need for better understanding and management of scleroderma complications, especially gastrointestinal and lung disease.

Purpose of the Study:

  • To summarize advancements in scleroderma research methodology and clinical trial design.
  • To highlight emerging insights into scleroderma pathogenesis and potential therapeutic targets.

Main Methods:

  • Review of recently published guidelines for clinical trials in systemic sclerosis.
  • Analysis of literature concerning scleroderma management and pathogenesis.

Main Results:

  • Publication of new guidelines by the American College of Rheumatology Committee on Design and Outcomes in Clinical Trials in Systemic Sclerosis.
  • Emphasis on the need for well-designed, prospective, and controlled studies to evaluate new treatments.
  • Identification of potential new targets for scleroderma treatment based on pathogenesis insights.

Conclusions:

  • While no new agents were studied, significant improvements in research methodology and trial design for scleroderma were achieved.
  • Future research should prioritize treatment options and foster large, collaborative, well-designed studies.
  • Understanding scleroderma pathogenesis offers promising avenues for novel therapeutic strategies.

Related Experiment Videos